

February 14, 2022

DCS-CRD BSE Limited First Floor, New Trade Wing Rotunda Building, Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400 023 Fax No.2272 3121/2037/2039 Stock Code: 543213	Listing Compliance National Stock Exchange of India Ltd. Exchange Plaza, 5 th Floor Plot No.C/1, 'G'Block, Bandra- Kurla Complex Bandra East Mumbai 400 051 Fax No.2659 8237/8238 Stock Code: ROSSARI
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir/Madam,

Subject: Q3 & 9M FY22 Press Release

Please find enclosed a copy of the Press Release for the quarter and nine months ended December 31, 2021.

The same may please be taken on record and suitably disseminated to all concerned.

Thanking you,

Yours Sincerely,
For Rossari Biotech Limited



Parul Gupta
Company Secretary & Compliance Officer
Membership No.: A38895

Encl.: as above

ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company)

Regd. Office : 201 A & B, Akruti Corporate Park, Next to GE Gardens, LBS Marg, Kanjurmarg (W). Mumbai - 400078. India. T +91-22-6123 3800 F +91-22-2579 6982

Factory : Plot No. 10 & 11, Survey No. 90/1/10 & 90/1/111/1, Kumbharwadi, Village Naroli, Dadra & Nagar Haveli (U.T.), Silvassa - 396 235. India. T 0260 - 669 3000

E info@rossarimail.com W www.rossari.com

CIN: L24100MH2009PLC194818



Rossari Biotech Limited

Corporate Office: 201 A & B Ackruti Corporate Park LBS Marg Next to G. E. Gardens, Kanjurmarg West,
Mumbai, Maharashtra 400078

Rossari Biotech announces Q3 & 9M FY22 results

<u>Q3 FY22</u>	<u>9M FY22</u>
Revenues at Rs. 428.4 Cr, higher by 104.0% YoY	Revenues at Rs. 1044.0 Cr, higher by 112.6% YoY
EBITDA improves by 37.4% YoY to Rs. 46.7 Cr	EBITDA improve by 45.6% YoY to Rs. 127.8 Cr
PAT at Rs. 22.5 Cr, higher by 4.3% YoY	PAT at Rs. 73.3 Cr, higher by 26.7% YoY

Mumbai, February 14, 2022: Rossari Biotech Limited (Rossari), a Speciality-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries, has announced its financial results for the quarter and nine months ended December 31, 2021.

Consolidated: Q3 FY22 performance overview compared with Q3 FY21

- Revenues from operations stood at Rs. 428.4 crore as against Rs. 210.0 crore
- EBITDA at Rs. 46.7 crore as against Rs. 34.0 crore
 - EBITDA margin at 10.9% as against 16.2%
- PAT stood at Rs. 22.5 crore as against Rs. 21.6 crore
- EPS (Diluted) stood at Rs. 4.07 as against Rs. 4.11

Consolidated: 9M FY22 performance overview compared with 9M FY21

- Revenues from operations stood at Rs. 1044.0 crore as against Rs. 491.1 crore
- EBITDA at Rs. 127.8 crore as against Rs. 87.8 crore, higher by 45.6%
 - EBITDA margin at 12.2% as against 17.9%
- PAT stood at Rs. 73.3 crore as against Rs. 57.8 crore, higher by 26.7%
- EPS (Diluted) stood at Rs. 13.29 as against Rs. 11.12

Note:

- 1) All figures, unless mentioned otherwise, are on a consolidated basis

- 2) *EPS not annualized*
- 3) *Rossari completed the acquisition of 65% equity shares of Unitop Chemicals w.e.f August 26, 2021 and of 76% equity shares of Tristar Intermediates w.e.f August 30, 2021. Accordingly, the Q3 & 9M FY22 results include consolidation of Unitop and Tristar performance from the date of acquisition till 31st December 2021 and hence are not comparable with the previous periods.*

Standalone: Q3 & 9M FY22 performance compared with Q3 & 9M FY21

- *Rossari registered steady organic revenue growth of 30.6% in Q3 FY22 and 65.8% in 9M FY22*

Commenting on the performance for the quarter, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said

“We have delivered steady performance during the quarter despite a challenging inflationary macro-environment. Our HPPC business reported healthy Y-o-Y sales growth supported by stable traction in FMCG, anti-viral & personal hygiene product portfolio volumes. TSC and AHN segments also delivered Y-o-Y topline growth driven by a pickup in demand in domestic and export markets. We are pleased to share that this is the first full quarter of consolidation of our recent acquisitions of Unitop and Tristar in Rossari’s performance. Both these companies delivered growth during the period, which assisted overall performance.

The raw material situation remained challenging in Q3 as well. In order to offset these persistent raw material pressures, we have been undertaking price hikes wherever possible. However, raw material volatility has impacted our profitability performance during the quarter.

On the business front, our latest acquisition of Romakk Chemicals has now been consolidated with effect from December 01, 2021. The timely integration of Romakk will further strengthen our presence in the textile and Home and Personal Care segment, going forward. The blend of capabilities from all our recent strategic acquisitions will enable us to build presence and gain scale in our key segments, thus accelerating growth for Rossari.

The Specialty Chemicals industry in India is fast progressing with multiple strong growth prospects ahead. With a strong balance sheet, adequate manufacturing capacities, and a solid product portfolio, we are well-poised to capitalize on the upcoming opportunities in this space. Furthermore, stabilization of the macro-economic environment will enable us to deliver strong performance, going forward.”

Key Developments:

Integration of Romakk Chemicals successfully completed

- Rossari acquired 50.1% stake of Romakk Chemicals Pvt Ltd w.e.f. December 01, 2021. Accordingly, this has been consolidated as JV in Q3 FY22 results
- Romakk has been delivering encouraging performance on the back of increasing demand and volume off-take in the markets.
- Going forward this integration will further strengthen Rossari's presence in textile and home & personal care segment

<End>

About Rossari Biotech Limited:

Rossari Biotech Limited (Rossari) (BSE: 543213, NSE: ROSSARI), is a Speciality-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries. Headquartered at Mumbai, India, the Company operates strategically located manufacturing facilities at Silvassa and Dahej. The Company offers tailor-made solutions for Home, Personal Care and Performance chemicals (HPPC), Textile speciality chemicals and Animal Health and Nutrition (AHN). With differentiated product offerings, Rossari caters to an array of applications across FMCG, Home care, Industrial Cleaning, Personal Care, Textile Speciality Chemicals, Performance Chemicals, the Animal Health and Nutrition and Pet Care businesses. The Company has an extensive and a dedicated network of distributors spread all over India.

For more information, please visit www.rossari.com OR contact:

Manasi Nisal

Rossari Biotech Limited

Tel: +91 22 6123 3800

Email: manasi.nisal@rossarimail.com

Anoop Poojari / Aesha Shah

CDR India

Tel: +91 98330 90434 / 9867250569

Email: anoop@cdr-india.com /
aesha@cdr-india.com

DISCLAIMER:

Certain statements and opinions with respect to the anticipated future performance of Rossari Biotech Limited in the press release ("forward-looking statements"), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to be correct. Such forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changes in economic, political, regulatory, business or other market conditions. Such forward-looking statements only speak as at the date the press release is provided to the recipient and Rossari Biotech Limited is not under any obligation to update or revise such forward-looking statements to reflect new events or circumstances. No representation or warranty (whether express or implied) is given in respect of any information in this press release or that this press release is suitable for the recipient's purposes. The delivery of this press release does not imply that the information herein is correct as at any time subsequent to the date hereof and Rossari Biotech Limited has no obligation whatsoever to update any of the information or the conclusions contained herein or to correct any inaccuracies which may become apparent subsequent to the date hereof.